Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. - Wikidata - awgldk - TriplyDB

Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

http://www.wikidata.org/entity/Q36210186

about

Ebola virus vaccines: an overview of current approaches Middle East respiratory syndrome: obstacles and prospects for vaccine development Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics Virus-based nanoparticles as platform technologies for modern vaccines.An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.Single Domain Antibodies as New Biomarker Detectors.Alphavirus Replicon DNA Vectors Expressing Ebola GP and VP40 Antigens Induce Humoral and Cellular Immune Responses in Mice.Replication-incompetent rabies virus vector harboring glycoprotein gene of lymphocytic choriomeningitis virus (LCMV) protects mice from LCMV challenge.Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever

P2860

Q26999232-B4A17167-F51B-4D83-A03C-1B6B620FEBAB Q27013314-C701CA4F-82B4-4DFA-A74E-AA2586FBFD38 Q27334697-0471F156-78A6-49DD-A25F-F5F4793D6B9F Q35184188-44B04F6D-DA9E-499E-AF9E-684F94C20E0C Q36043269-839B1262-47B1-4F3C-8055-59B07B54358B Q37560824-68E8A297-EAA3-414E-A967-304352690028 Q38363535-1EAE44DC-7A2C-47EB-BF74-16528E5F010C Q38702017-4879D0C1-9842-44A5-B764-8C50D7FD2B2E Q40095257-0298EDB2-8082-46B5-BB1D-300ED210A7C8 Q47099886-08281A0E-43DB-433F-8CA9-9ADE1E659F87 Q47548508-825F6247-C59A-4565-B061-D962119AACD4 Q52586088-FDCD604A-4BA0-48C8-9DDA-65A05210C01E Q57476548-1B18E4E8-A6A9-4B76-814B-C732E6976F75

P2860

Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

http://www.wikidata.org/entity/Q36210186

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Further characterization of th ...... sing Ebola virus glycoprotein.

@ast

Further characterization of th ...... sing Ebola virus glycoprotein.

@en

type

label

Further characterization of th ...... sing Ebola virus glycoprotein.

@ast

Further characterization of th ...... sing Ebola virus glycoprotein.

@en

prefLabel

Further characterization of th ...... sing Ebola virus glycoprotein.

@ast

Further characterization of th ...... sing Ebola virus glycoprotein.

@en

P1433

Q36210186-54E81484-5A55-4F77-9EE9-F0ECB90D177C

P1476

Q36210186-F4645BA3-4724-4D97-8AFE-D7B4357668CD

P2093

Q36210186-2E51CCA2-3FCA-410D-9F65-81861A6B2E17

Q36210186-8C077126-96DA-4BE3-A4FF-43308E551DFC

Q36210186-98A984BD-9805-466E-97BB-F911BD61A7D3

Q36210186-FD970688-5583-4431-9543-7B89C08593B2

P2860

Q36210186-015F80DE-894E-4EE3-9E7D-FBD9F6534175

Q36210186-0CBDBF80-C7DB-429C-97F5-52D34F866253

Q36210186-0EA8CCC6-6CAA-484D-A1F8-4E3DC9ED4748

Q36210186-16A04F74-8989-426C-B265-8DC40E068319

Q36210186-1C797C7C-5755-4778-B533-FAF8CD41742D

Q36210186-20C4BF64-97CD-4C83-86DE-8BF9DAF835AD

Q36210186-234AD245-C434-43E9-8D26-CB12C75A584B

Q36210186-2A804BF2-4A94-4C8A-A8D1-EE71EB269EA9

Q36210186-2DC18D1F-4EAF-4A94-A2D6-1F4C64DE4680

Q36210186-2E1BEF50-F61C-4D7A-9B8C-5E2240F004BB

P304

Q36210186-0131A507-41FD-4057-AB8B-7FAD28E282EF

P31

Q36210186-B1728A66-02B8-48BF-AB9A-11189B3E1983

P356

Q36210186-4783996A-F4BC-42B4-951A-1565ACF0F11C

P407

Q36210186-2B3911B1-E73D-42C0-8131-93E4A0FEBD78

P433

Q36210186-5122CEAB-0DEE-4E13-9699-F7283701393D

P478

Q36210186-A230AF9D-89DC-47E2-A3FD-9E9AEDD194DB

P50

Q36210186-4937FA07-F0F2-42BC-88DF-44E859A3D652

Q36210186-7716D120-E113-4283-8154-A06C633BDE6D

P577

Q36210186-A5E558A3-0290-470D-9D7F-4225FA3CE0EF

P5875

Q36210186-A385E6A0-8EB7-4A47-9832-1B54B19715E8

P698

Q36210186-EDF707C5-F3C7-4689-AD50-E3FE40B64A70

P921

Q36210186-0D258A4F-45B9-4347-98AF-281799C16BA8

Q36210186-9FDB357D-33B6-4C87-9676-EDAD00C723FF

Q36210186-B6CD09D5-F021-4FAA-A7B5-D5154ED85F29

P932

Q36210186-F9D3EC70-D01C-46A2-B4A3-C799D0F9CA2E

P356

J.VACCINE.2012.07.073

P1433

P1476

Further characterization of th ...... sing Ebola virus glycoprotein.

@en

P2093

Christoph Wirblich

http://www.w3.org/2001/XMLSchema#string

Joseph E Blaney

http://www.w3.org/2001/XMLSchema#string

Kurt Cooper

http://www.w3.org/2001/XMLSchema#string

Matthias J Schnell

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple Ebola Virus Transmission Events and Rapid Decline of Central African Wildlife

Development of a preventive vaccine for Ebola virus infection in primates

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species

Characterization of a single-cycle rabies virus-based vaccine vector.

Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge.

Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.

A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies

Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

P304

6136-6141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2012.07.073

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Peter B. Jahrling

P577

2012-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230655881

http://www.w3.org/2001/XMLSchema#string

P698

22884661

http://www.w3.org/2001/XMLSchema#string

P921

Vaccine against Ebola

P932

3434297

http://www.w3.org/2001/XMLSchema#string